-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
SHANGHAI, CHINA & HONG KONG, March 10, 2022 /PRNewswire/ -- A leading commercial-stage innovative biopharmaceutical company dedicated to developing, manufacturing and marketing first-in-class and/or best-in-class hematologic and solid tumor therapies – Antengene Pharma Co.
As a novel PD-L1/4-1BB bispecific antibody, ATG-101 can block immunosuppressive PD-L1/PD-1 binding while conditionally activate 4-1BB co-stimulatory signal, thereby activating anti-tumor Immune effector cells enhance safety while enhancing efficacy
This clinical study is led by Shanghai Dongfang Hospital and is planned to be carried out in 4 research centers in China
The principal investigator, Professor Guo Ye, deputy director of the Department of Oncology at Shanghai Dongfang Hospital and director of the Phase I Clinical Center, said: "At present, many patients with malignant tumors are resistant or difficult to existing treatments (including chemotherapy, targeted therapy, and immunotherapy).
Dr.
About ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody being developed for the treatment of metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL)
About Antengene
Antengene Pharmaceuticals Co.
forward-looking statements
Forward-looking statements made herein relate only to events or information as of the date on which they are made
Source: Antengene Pharmaceuticals Ltd.
